

## Freedom of Information Act Request

I am writing to request information under the Freedom of Information Act 2000.

Q1. How many patients has your Trust treated in the past 12 months (January - December 2025) for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Trust do you refer patients needing treatment to?

Based on prescribing records held within the Trust's Chemocare system, 72 patients received active treatment for Chronic Lymphocytic Leukaemia (CLL) during the period 1 January to 31 December 2025.

Scope and limitations of the data

The Trust does not hold a single, definitive dataset that captures all patients diagnosed with CLL regardless of treatment status. Chemocare records patients who received systemic anti-cancer therapy and does not capture patients who are managed without active treatment.

CLL is a condition in which a significant proportion of patients are managed on a "watch and wait" pathway. Patients who did not receive active treatment during the period specified will not appear in Chemocare prescribing data and are therefore not included in the figure provided.

Accordingly, the number reported:

- Represents patients who received active treatment during the specified period, and
- Should not be interpreted as the total number of patients with CLL under the Trust's care or the overall prevalence of CLL.

Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated by the Trust in the past 6 months on the following treatments:

- BR (bendamustine + rituximab)
- Brukinsa (zanubrutinib)
- Calquence (acalabrutinib)
- Calquence (acalabrutinib) + Gazyva (obinutuzumab)
- Calquence (acalabrutinib) + Venclyxto (venetoclax)
- Calquence (acalabrutinib) + Venclyxto (venetoclax) + Gazyva (obinutuzumab)
- FCR (fludarabine + cyclophosphamide + rituximab)
- Fludarabine Monotherapy
- Gazyva (obinutuzumab) + chlorambucil
- Imbruvica (ibrutinib)
- Venclyxto (venetoclax)
- Venclyxto (venetoclax) + Gazyva (obinutuzumab)
- Venclyxto (venetoclax) + rituximab
- Zydelig (idelalisib) + rituximab
- Imbruvica (Ibrutinib) +Venclyxto (venetoclax)
- Any other systemic anti-cancer therapy

DBTH holds the information on the subject you have requested. However, I advise you that we will not be able to answer your request without exceeding the appropriate limit. This is because our pharmacy system doesn't store diagnosis data, so we're unable to determine this against

the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Section 12 of the Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit, We have estimated that it would take more than 18 hours to carry out a manual search to locate, retrieve, and extract all the information you have requested. In this situation the associated cost would therefore exceed the appropriate fee limit of £450 set out under Freedom of Information & Data Protection (Appropriate Limit and Fees) Regulations 2007.

The fee limit specified in regulations for NHS trusts represents the cost of one person spending 2½ working days at a rate of £25 per hour determining whether the Trust holds the information sought and then locating, retrieving and extracting that information.

Q3. How many Chronic Lymphocytic Leukaemia (CLL) patients have received treatment for relapsed/refractory CLL in the past 6 months with the following:

- Brukinsa (zanubrutinib)
- Calquence (acalabrutinib)
- Imbruvica (ibrutinib)
- Venclyxto (venetoclax)
- Zydelig (idelalisib) + rituximab
- Any other systemic anti-cancer therapy

DBTH holds the information on the subject you have requested. However, I advise you that we will not be able to answer your request without exceeding the appropriate limit. This is because our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Section 12 of the Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit, We have estimated that it would take more than 18 hours to carry out a manual search to locate, retrieve, and extract all the information you have requested. In this situation the associated cost would therefore exceed the appropriate fee limit of £450 set out under Freedom of Information & Data Protection (Appropriate Limit and Fees) Regulations 2007.

Our Ref: 70  
January 2026

The fee limit specified in regulations for NHS trusts represents the cost of one person spending 2½ working days at a rate of £25 per hour determining whether the Trust holds the information sought and then locating, retrieving and extracting that information.

Q4. If your Trust does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If yes, please can you provide details of the ongoing trials.

EPIC: A non-interventional, observational cohort study of Chronic Lymphocytic Leukaemia patients treated with acalabrutinib in the first-line setting through the UK Early Access Programme: Early access Programme outcomes In a Calabrutinib

Closed to recruitment in follow up

11 participants recruited

Planned closing date 30/09/2027

FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab

Closed to recruitment in follow up.

10 Participants recruited

Study closure date 30/05/2030

If you are not satisfied with the handling of your request, you have the right to request an internal review. Requests for an internal review should be submitted within 40 working days from the date of this response, and should be addressed to d.wraith@nhs.net.

If you remain dissatisfied after the internal review, you have the right to appeal to the Information Commissioner's Office (ICO). The ICO can be contacted at:

Information Commissioner's Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
Website: <https://ico.org.uk/make-a-complaint/>

Our Ref: 70  
January 2026